BioCryst Pharmaceuticals | BCRX - Betriebsergebnis

Aktienkurs
9.56
Täglich Wechseln
-0.33 -3.34%
Monatlich
12.60%
Jährlich
40.18%
Q2 Prognose
9.30




Betriebsergebnis Veränderung Datum
Alnylam Pharmaceuticals USD 29.4M 59.36M 2025-12
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Chugai Pharma JPY 169.01B 12.52B 2025-12
Daiichi Sankyo JPY 89.54B 42.01B 2025-12
DBV Technologies USD -34.28M 6.83M 2025-09
Enanta Pharmaceuticals USD -23.54M 98.15M 2024-12
Gilead Sciences USD 2.96B 551M 2025-12
GlaxoSmithKline GBP 1.44B 1.35B 2025-12
Glaxosmithkline GBP 2.3B 1.46B 2025-12
Incyte USD 383.88M 47.43M 2025-12
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
Karyopharm Therapeutics USD -17.84M 13.44M 2025-12
Neurocrine Biosciences USD 227.9M 11.4M 2025-12
Novavax USD 20.94M 100.32M 2025-12
PTC Therapeutics USD -81.62M 85.11M 2025-12
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Roche Holding CHF 9.56B 3.8B 2025-12
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
Vertex Pharmaceuticals USD 1.26B 24.5M 2025-12